- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.10. | Azitra erhält Non-Compliance-Mitteilung der NYSE American | 1 | Investing.com Deutsch | ||
| 03.10. | Azitra receives notice of non-compliance from NYSE American | 1 | Seeking Alpha | ||
| 03.10. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| AZITRA Aktie jetzt für 0€ handeln | |||||
| 03.10. | Azitra receives NYSE American non-compliance notice | 1 | Investing.com | ||
| 03.10. | Azitra, Inc.: Azitra Receives Notice of Non-Compliance from NYSE American | 101 | PR Newswire | BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies... ► Artikel lesen | |
| 29.08. | Azitra, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Azitra stock soars after first patient dosed in Phase 1/2 trial | 3 | Investing.com | ||
| 27.08. | Azitra doses first patient in phase 1/2 trial for cancer therapy rash | 2 | Investing.com | ||
| 27.08. | Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash | 252 | PR Newswire | BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 22.08. | Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole-EpicQuest, Zoom, Azitra Stocks In Focus | 4 | Benzinga.com | ||
| 20.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Azitra reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates | 283 | PR Newswire | BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 11.08. | Azitra to implement 1-for-6.66 reverse stock split | 1 | Seeking Alpha | ||
| 11.08. | Azitra, Inc. Announces Reverse Stock Split | 180 | PR Newswire | Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025
BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR)... ► Artikel lesen | |
| 11.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Azitra, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.07. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 03.07. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,260 | +1,80 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,162 | -0,61 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| BIONTECH | 87,95 | +0,11 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen |
Das Unternehmen AZITRA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,018 (-2,46 %) liegt der Kurs bei 0,698 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.